(Q35999197)

English

Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study (English)

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

rheumatoid arthritis

0 references

1

object named as

Takao Koike

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Hisashi Yamanaka

8

object named as

Hisashi Yamanaka

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

author name string

Masayoshi Harigai

2

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Shigeko Inokuma

3

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Naoki Ishiguro

4

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Junnosuke Ryu

5

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Tsutomu Takeuchi

6

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Yoshiya Tanaka

7

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Koichi Fujii

9

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Takunari Yoshinaga

10

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Bruce Freundlich

11

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Michio Suzukawa

12

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

publication date

18 February 2011

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Rheumatology International

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

32

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

6

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

1617-1624

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364424

2 October 2017

Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364424

2 October 2017

Definitions of remission for rheumatoid arthritis and review of selected clinical cohorts and randomised clinical trials for the rate of remission.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364424

2 October 2017

What should be our treatment goal in rheumatoid arthritis today?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364424

2 October 2017

Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364424

2 October 2017

Guidelines for the proper use of etanercept in Japan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364424

2 October 2017

Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364424

2 October 2017

Anti-TNF-alpha therapies: they are all the same (aren't they?).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364424

2 October 2017

The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364424

2 October 2017

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364424

2 October 2017

Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364424

2 October 2017

Strategies for targeting tumour necrosis factor in IBD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364424

2 October 2017

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364424

2 October 2017

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364424

2 October 2017

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

https://api.crossref.org/works/10.1007%2FS00296-011-1807-0

21 January 2018

Risk factors associated with the cumulative survival of low-dose methotrexate in 273 Japanese patients with rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-011-1807-0

21 January 2018

Etanercept is effective in patients with rheumatoid arthritis with no response to infliximab therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364424

23 September 2018

Etanercept--infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNFalpha

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364424

23 September 2018

Guidelines for the management of rheumatoid arthritis: 2002 Update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364424

23 September 2018

Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE registry at Karolinska University Hospital

1 reference

https://api.crossref.org/works/10.1007%2FS00296-011-1807-0

21 January 2018

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21331576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21331576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

1 reference

https://pubmed.ncbi.nlm.nih.gov/21331576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept

1 reference

https://pubmed.ncbi.nlm.nih.gov/21331576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of the anti-TNF biologic agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/21331576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein

1 reference

https://pubmed.ncbi.nlm.nih.gov/21331576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis?

1 reference

https://pubmed.ncbi.nlm.nih.gov/21331576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21331576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21331576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/21331576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00296-011-1807-0

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35999197&oldid=2198053587"